Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
JAMA. 2021 Oct 26;326(16):1614-1621. doi: 10.1001/jama.2021.18236.
Mendelian randomization (MR) studies use genetic variation associated with modifiable exposures to assess their possible causal relationship with outcomes and aim to reduce potential bias from confounding and reverse causation.
To develop the STROBE-MR Statement as a stand-alone extension to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guideline for the reporting of MR studies.
DESIGN, SETTING, AND PARTICIPANTS: The development of the STROBE-MR Statement followed the Enhancing the Quality and Transparency of Health Research (EQUATOR) framework guidance and used the STROBE Statement as a starting point to draft a checklist tailored to MR studies. The project was initiated in 2018 by reviewing the literature on the reporting of instrumental variable and MR studies. A group of 17 experts, including MR methodologists, MR study design users, developers of previous reporting guidelines, and journal editors, participated in a workshop in May 2019 to define the scope of the Statement and draft the checklist. The draft checklist was published as a preprint in July 2019 and discussed on the preprint platform, in social media, and at the 4th Mendelian Randomization Conference. The checklist was then revised based on comments, further refined through 2020, and finalized in July 2021.
The STROBE-MR checklist is organized into 6 sections (Title and Abstract, Introduction, Methods, Results, Discussion, and Other Information) and includes 20 main items and 30 subitems. It covers both 1-sample and 2-sample MR studies that assess 1 or multiple exposures and outcomes, and addresses MR studies that follow a genome-wide association study and are reported in the same article. The checklist asks authors to justify why MR is a helpful method to address the study question and state prespecified causal hypotheses. The measurement, quality, and selection of genetic variants must be described and attempts to assess validity of MR-specific assumptions should be well reported. An item on data sharing includes reporting when the data and statistical code required to replicate the analyses can be accessed.
STROBE-MR provides guidelines for reporting MR studies. Improved reporting of these studies could facilitate their evaluation by editors, peer reviewers, researchers, clinicians, and other readers, and enhance the interpretation of their results.
孟德尔随机化(MR)研究利用与可改变的暴露相关的遗传变异来评估它们与结果的可能因果关系,并旨在减少混杂和反向因果关系引起的潜在偏倚。
制定 STROBE-MR 声明,作为对 STROBE(加强观察性研究的报告)指南的独立扩展,用于报告 MR 研究。
设计、设置和参与者:STROBE-MR 声明的制定遵循增强健康研究的质量和透明度(EQUATOR)框架指南,并以 STROBE 声明为起点,起草一份针对 MR 研究的定制清单。该项目于 2018 年启动,通过审查关于工具变量和 MR 研究报告的文献。2019 年 5 月,一组 17 名专家(包括 MR 方法学家、MR 研究设计使用者、以前报告指南的开发者和期刊编辑)参加了一个研讨会,以确定声明的范围并起草清单。清单草案于 2019 年 7 月作为预印本发布,并在预印本平台、社交媒体和第四届孟德尔随机化会议上进行了讨论。随后根据意见对清单进行了修订,在 2020 年进一步完善,并于 2021 年 7 月定稿。
STROBE-MR 清单分为 6 个部分(标题和摘要、引言、方法、结果、讨论和其他信息),包括 20 个主要项目和 30 个子项目。它涵盖了评估 1 种或多种暴露和结果的 1 样本和 2 样本 MR 研究,并解决了遵循全基因组关联研究并在同一篇文章中报告的 MR 研究。清单要求作者说明为什么 MR 是解决研究问题的有用方法,并陈述预先指定的因果假设。必须描述遗传变异的测量、质量和选择,并应很好地报告评估 MR 特定假设的有效性。关于数据共享的项目包括报告何时可以访问用于复制分析的数据和统计代码。
STROBE-MR 为报告 MR 研究提供了指南。改进这些研究的报告可以促进编辑、同行评审员、研究人员、临床医生和其他读者对其进行评估,并增强对其结果的解释。